Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Profit After Tax: 2013-2024

Historic Profit After Tax for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$413.6 million.

  • ImmunityBio's Profit After Tax rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.69%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • ImmunityBio's Profit After Tax amounted to -$413.6 million in FY2024, which was up 29.15% from -$583.9 million recorded in FY2023.
  • ImmunityBio's 5-year Profit After Tax high stood at -$224.2 million for FY2020, and its period low was -$583.9 million during FY2023.
  • In the last 3 years, ImmunityBio's Profit After Tax had a median value of -$417.3 million in 2022 and averaged -$471.6 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 56.05% in 2021, then rose by 29.15% in 2024.
  • Over the past 5 years, ImmunityBio's Profit After Tax (Yearly) stood at -$224.2 million in 2020, then crashed by 56.05% to -$349.8 million in 2021, then dropped by 19.29% to -$417.3 million in 2022, then slumped by 39.91% to -$583.9 million in 2023, then increased by 29.15% to -$413.6 million in 2024.